Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Articles|February 1, 2002
- Pharmaceutical Technology-02-02-2002
- Volume 26
- Issue 2
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part I
Author(s)Orlando López
A combination of security technologies, infrastructures, and cryptographic product-services families can help companies satisfy the requirements of 21 CFR Part 11.
Advertisement
Articles in this issue
over 24 years ago
Using Earned-Value Analysis to Better Manage Projectsover 24 years ago
Microbial Bioburden on Oral Solid Dosage Formsover 24 years ago
Modernizing Pharmaceutical Manufacturingover 24 years ago
Outsourcing OutlookAdvertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
2
Germany’s Medical Biotechnology Sector is Flourishing
3
First-in-Human Trial Speed: Why FDA Trails China
4
Formulation Strategies for Next-Generation Multiagonists
5